UNSPSC 51124201: Barucainide

This classification denotes an antiarrhythmic agent with the molecular formula C22H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 14NFL30YOH, chemically known as 4-((1,3-dihydro-6-methyl-4-benzylfuro(3,4-c)pyridin-7-yl)oxy)-n-isopropylbutylamine monohydrochloride but more generally known as barucainide, which bears US NIH Compound Identifier 146794. European Medicines Agency schedules Barucainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06106MIG.

UNSPSC 51124201 Barucainide is a Commodity code covering emergency and critical-care medications supplied to state and local public-health and public-safety agencies. State and local governments procure these products primarily for emergency medical services, including fire departments and emergency response teams. The Tampa Fire Rescue procures advanced life support medications including epinephrine, labetalol, adenosine, and diltiazem through sealed-bid IFB competitions, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) establishes master agreements for generic multi-source pharmaceuticals and OTC products across member state and local facilities in multiple states including Oregon. The issuing bodies include municipal fire departments, state health and human services agencies, and cooperative purchasing alliances representing multiple jurisdictions. Texas Health and Human Services Commission has also begun exploratory market intelligence gathering on direct-to-manufacturer prescription models, signaling emerging interest in alternative supply-chain arrangements beyond traditional wholesaler networks.

Recent activity spans Florida, Minnesota (with Oregon participation through MMCAP), and Texas. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026 and an estimated contract value of $40,000; the solicitation required 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials with nine-month minimum expiration dates and delivery within ten calendar days of order. The Minnesota Department of Administration's MMCAP issued an RFP (Solicitation S1070000015802) with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026 and contract terms of two years for new vendors. The Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, exploring direct-to-manufacturer prescription capabilities as a preliminary market-intelligence phase before formal solicitation. SLBE set-asides and 5 percent bid discounts appear in Tampa's solicitation; no disadvantaged-enterprise restrictions are identified in MMCAP or the Texas RFI.